Zoe V Fox

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors
    Zoe V Fox
    Copenhagen HIV Programme, Medical Faculty at University of Copenhagen, Denmark
    AIDS 21:2033-42. 2007
  2. ncbi Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2
    Zoe Fox
    Hvidovre University Hospital, DK 2650 Hvidovre, Denmark
    HIV Med 8:112-23. 2007
  3. ncbi Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen
    Zoe Fox
    Copenhagen HIV Programme, University of Copenhagen Rigshospitalet, Copenhagen, Denmark
    AIDS 22:2279-89. 2008
  4. ncbi Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA
    Zoe V Fox
    Copenhagen HIV Programme, Copenhagen, Denmark
    Antivir Ther 16:781-5. 2011
  5. ncbi Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy
    Anna Maria Geretti
    Department of Virology, Royal Free Hampstead NHS Trust, London, UK
    J Acquir Immune Defic Syndr 52:569-73. 2009

Detail Information

Publications5

  1. ncbi The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors
    Zoe V Fox
    Copenhagen HIV Programme, Medical Faculty at University of Copenhagen, Denmark
    AIDS 21:2033-42. 2007
    ..We compared PI/r resistance levels ascribed by four GIS and examined their abilities to predict HIV-RNA reductions after starting a PI/r-based regimen (baseline)...
  2. ncbi Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2
    Zoe Fox
    Hvidovre University Hospital, DK 2650 Hvidovre, Denmark
    HIV Med 8:112-23. 2007
    ..The IL-2 induction phase consists of three dosing cycles over 6-8 months (7.5 MIU twice a day, for 5 days every 8 weeks)...
  3. ncbi Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen
    Zoe Fox
    Copenhagen HIV Programme, University of Copenhagen Rigshospitalet, Copenhagen, Denmark
    AIDS 22:2279-89. 2008
    ..Limited data exist to guide clinical practice on the best interruption strategy to use...
  4. ncbi Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA
    Zoe V Fox
    Copenhagen HIV Programme, Copenhagen, Denmark
    Antivir Ther 16:781-5. 2011
    ..There are limited data showing the frequency of resistance testing in routine clinical practice following these recommendations...
  5. ncbi Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy
    Anna Maria Geretti
    Department of Virology, Royal Free Hampstead NHS Trust, London, UK
    J Acquir Immune Defic Syndr 52:569-73. 2009
    ..There are conflicting data on the impact of low-frequency transmitted drug-resistant mutants on responses to first-line highly active antiretroviral therapy (HAART)...